GlaxoSmithKline Newswire

GlaxoSmithKline Newswire

Comprehensive Real-Time News Feed for GlaxoSmithKline.

Results 1 - 20 of 7,083 in GlaxoSmithKline

  1. James Noble, Adaptimmune CEO, to Participate in Upcoming Leerink...Read the original story

    1 hr ago | Customer Interaction Solutions

    ... also developing its NY-ESO SPEAR T-cell program under a strategic collaboration and license agreement with GlaxoSmithKline. The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit ...

    Comment?

  2. GlaxoSmithKline PLC (GSK) Shares Sold by Van ECK Associates CorpRead the original story w/Photo

    2 hrs ago | The Breeze

    Van ECK Associates Corp trimmed its stake in shares of GlaxoSmithKline PLC by 22.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission . The firm owned 311,850 shares of the pharmaceutical company's stock after selling 92,681 shares during the quarter.

    Comment?

  3. Bayer Appoints Head Of Global Innovation & Development For Consumer HealthRead the original story

    17 hrs ago | BioSpace

    ... leading global research and development organizations at Bayer, Merck (MSD) as well as Schering-Plough and GlaxoSmithKline, was leading successful over-the-counter switches of prescription medicines, creating state-of-the-art consumer testing ...

    Comment?

  4. Norwalk company acquires South Carolina drug plantRead the original story w/Photo

    19 hrs ago | Connecticut Post

    ... use as an outsourced drug production and packaging facility in a deal announced Sept. 21, 2017. (PRNewsFoto/GlaxoSmithKline Consumer Healthcare) less GSK packages of Alli on display, with the drug having been manufactured at an Aiken, S.C. plant ...

    Comment?

  5. GlaxoSmithKline plc (GSK) Trading Up 1%Read the original story w/Photo

    20 hrs ago | The Breeze

    GlaxoSmithKline plc was up 1% on Thursday . The stock traded as high as GBX 1,471.50 and last traded at GBX 1,468 .

    Comment?

  6. South Texas Money Management Ltd. Acquires Shares of 5,426 GlaxoSmithKline PLCRead the original story w/Photo

    23 hrs ago | IntersportsWire

    South Texas Money Management Ltd. acquired a new position in shares of GlaxoSmithKline PLC during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 5,426 shares of the pharmaceutical company's stock, valued at approximately $234,000.

    Comment?

  7. Avara Acquires Consumer Healthcare Facility From GlaxoSmithKline In Aiken, South CarolinaRead the original story w/Photo

    Wednesday | BioSpace

    The transaction is expected to complete on or before Avara Pharmaceutical Services is a state-of-the-art contract manufacturing and technical services organization providing both API formulation and manufacturing, along with secondary formulation, manufacturing and packaging of small molecule drugs, including highly potent compounds. Avara has secondary manufacturing technologies including granulation, coating, blending, encapsulation, compression and drying of tablets and capsules.

    Comment?

  8. ISPE 2017 Annual Meeting & Expo Keynote Speakers AnnouncedRead the original story

    Yesterday | PRWeb

    The International Society for Pharmaceutical Engineering announced its keynote speakers for their 2017 Annual Meeting & Expo . Taking place in San Diego, California, October 29 to November 1, keynote addresses will showcase global pharmaceutical industry leaders offering compelling and enlightening presentations spanning the product lifecycle.

    Comment?

  9. UK Trade Minister visits GlaxoSmithKline...Read the original story w/Photo

    Yesterday | Pakistan Christian Post

    Islamabad: September 21, 2017. As a part of his three-day visit to Pakistan, the UK Minister for Trade Policy Greg Hands visited GlaxoSmithKline's factory in Karachi to see first-hand how major British investors, like GSK, are successfully doing business in Pakistan, supporting the Pakistani economy and creating jobs whilst making good returns on investment.

    Comment?

  10. GlaxoSmithKline plc (GSK) Given Hold Rating at Deutsche Bank AGRead the original story w/Photo

    Yesterday | IntersportsWire

    ... on the stock. A number of other equities analysts also recently issued reports on GSK. Berenberg Bank raised GlaxoSmithKline plc from a hold rating to a buy rating and upped their price target for the company from GBX 1,850 ($24.94) to GBX 1,885 ...

    Comment?

  11. Thursday broker round-upRead the original story w/Photo

    Yesterday | Live Charts

    ... Overweight with a target price of 10,000p. BTG: Deutsche Bank reiterates Buy with a target price of 775p. GlaxoSmithKline: Deutsche Bank reiterates Hold with a target price of 1610p. Paddy Power Betfair: HSBC maintains Reduce with a target price of ...

    Comment?

  12. NPL mmW anerchoic chamberRead the original story w/Photo

    Yesterday | Electronics Weekly

    ... - SMEs, RTOs (research and technology orgaisations), and larger organisations including Rolls Royce and GlaxoSmithKline - which revealed many had not heard of NPL, or didn't know it provided services to industry. These services are based on accurate ...

    Comment?

  13. J P Morgan Chase & Co Reiterates Neutral Rating for GlaxoSmithKline PLCRead the original story w/Photo

    Yesterday | AmericanBankingNews.com

    ... equities research analysts also recently issued reports on the stock. Morgan Stanley downgraded shares of GlaxoSmithKline PLC from an "equal weight" rating to an "underweight" rating in a research note on Friday, September 8th. Argus reiterated a ...

    Comment?

  14. Theravance Biopharma Highlights Positive Headline Results From IMPACT ...Read the original story

    Wednesday | BioSpace

    Theravance Biopharma Highlights Positive Headline Results From IMPACT Study Of Trelegy Ellipta Announced By GlaxoSmithKline And Innoviva Inc. Single Inhaler Triple Therapy Met Study Primary Endpoint Demonstrating Reduction in Exacerbations Compared with Dual Therapies Anoro Ellipta and Relvar/Breo Ellipta in Patients with COPD Theravance Biopharma Entitled to Receive 85% Economic Interest in Trelegy Ellipta Royalties Paid by GlaxoSmithKline as Part of Agreement with Innoviva /PRNewswire/ -- Theravance Biopharma, Inc. today highlighted that GlaxoSmithKline plc and Innoviva, Inc. have reported positive headline results from the landmark Phase 3 IMPACT study of Trelegy Ellipta, the first and only FDA approved once-daily single inhaler triple therapy comprising an inhaled corticosteroid , long-acting muscarinic antagonist and long-acting beta agonist .

    Comment?

  15. Sir Andrew Witty takes on his second role in as many daysRead the original story w/Photo

    Wednesday | Daily Mail

    Never one to rest on his laurels, former GlaxoSmithKline boss Sir Andrew Witty has taken on his second role in as many days. The 53-year-old, who retired as GSK chief executive this year, was yesterday appointed to the advisory board of Synthego, a leading provider of genome engineering in the US.

    Comment?

  16. Daily Briefing: Insurer Hiscox hires former GCHQ bossRead the original story w/Photo

    Wednesday | Daily Mail

    ... will be a special adviser on cyber security. A three-in-one inhaler created by British pharmaceuticals giant GlaxoSmithKline has showed promising results in a trial. The drug maker hopes Trelegy could become a big seller to replace its older lung ...

    Comment?

  17. London close: Strength in Sterling puts a lid on stocksRead the original story w/Photo

    Wednesday | Live Charts

    ... for the first half of the year but remained cautious on the second half backdrop in the UK and France. GlaxoSmithKline advanced as it reported positive headline results from a phase-three impact study of Trelegy Ellipta, a triple-therapy inhaler for ...

    Comment?

  18. Sir Andrew Witty, Former CEO of GSK, Joins Synthego Advisory BoardRead the original story w/Photo

    Wednesday | Market Wire

    Synthego , a leading provider of genome engineering solutions, announces the appointment of Sir Andrew Witty, former CEO of GlaxoSmithKline and Director at UnitedHealth Group, to the Synthego advisory board. "Synthego's vision for automating biological research will revolutionize the industry by accelerating application development and enabling machine learning based insights.

    Comment?

  19. How the Internet of cells has biologists buzzingRead the original story w/Photo

    Wednesday | NatureNews

    ... in the tubes. One of the believers is George Okafo, a director of emerging platforms at the drug company GlaxoSmithKline (GSK) in Stevenage, UK. He thinks that cell-to-cell protrusions could explain why diseases such as Alzheimer's disease, ...

    Comment?

  20. GlaxoSmithKline And Innoviva Inc. Report Positive Headline Results...Read the original story

    Tuesday Sep 19 | BioSpace

    GlaxoSmithKline plc and Innoviva, Inc. today announced positive headline results from the landmark phase III IMPACT study of Trelegy Ellipta, the first and only FDA approved once-daily single inhaler triple therapy comprising an inhaled corticosteroid , long-acting muscarinic antagonist and long-acting beta agonist . Trelegy Ellipta is approved for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease who are receiving Breo and require additional bronchodilation or who are receiving Breo and Incruse .

    Comment?